BDRX Live signals | Maximize Profits with Getagraph.com

SELL 126952 min ago

@ $1.850

Issued: 13 Feb 2024 @ 09:30

Return: -50.01%

Previous signal: Feb 12 - 13:28

Previous signal: Buy

Return: 37.04 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally...

Stats
Today's Volume	175 862
Average Volume	3.19M
Market Cap	231 778
EPS	$0 ( 2023-07-28 )
Next earnings date	( $0 ) 2024-06-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0900
ATR14	$0.00900 (0.97%)

Volume Correlation

Long: -0.11 (neutral)

Short: -0.73 (moderate negative)

Signal:(45.856) Neutral

Biodexa Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Biodexa Pharmaceuticals Correlation - Currency/Commodity

0.58
( weak )

0.11
( neutral )

0.00
( neutral )

0.65
( moderate )

0.00
( neutral )

-0.84
( strong negative )

Biodexa Pharmaceuticals Financials

Annual	2023
Revenue:	$381 000
Gross Profit:	$-3.69M (-967.45 %)
EPS:	$-8.97

FY	2023
Revenue:	$381 000
Gross Profit:	$-3.69M (-967.45 %)
EPS:	$-8.97

FY	2022
Revenue:	$699 000
Gross Profit:	$-4.41M (-631.19 %)
EPS:	$-619.72

Financial Reports:

No articles found.

Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a drug delivery technology company, focuses on the bio-delivery and biodistribution of medicines in Belgium and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTD211, a long-acting formulation of brexpiprazole for the treatment of schizophrenia and adjunctive treatment of major depressive disorder; and MTX223, a long-acting injectable formulations of biologic products, such as mAbs or other high molecular weight proteins. It also offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.